Expanded international presence boosts Mindray's Q2 sales
This article was originally published in Clinica
Executive Summary
Chinese medical device manufacturer Mindray Medical International saw an almost doubling of its Q2 sales, helped by strong performances from both its domestic and newly-expanded international businesses. The Shenzhencompany saw its operations outside of China significantly boosted by the acquisition of Datascope's patient monitoring business in the US and Europe during the quarter (see Clinica No 1299, p 3). Mindray's international sales went up 139% to $87.8m, while the company's performance in China continued to be strong, with sales growing 59% to $57.9m. Total revenue (+99.5%) was$145.7m, while net income increased 55% to $35.2m.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.